New MagVenture Headquarters

MagVenture is expanding its headquarter in Denmark, adding another 3,600 new m2 office and production space, providing us with even more capacity to meet the growing market demand for TMS.
MagVenture TMS Therapy® is FDA cleared for:
“Treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.” and as "an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder"
MagVenture TMS Therapy® is CE approved for:
“Treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode.”